A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

[1] Donnadieu N(1991)Chemotherapy of non-small cell bronchial cancers. Meta-analysis of the literature as a function of the extent of the disease Rev Mal Respir 8 197-204

[2] Paesmans M(1995)Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials Bmj 311 899-909

[3] Sculier JP(1991)Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest oncology group experience J Clin Oncol 9 1618-1626

[4] Albain KS(2004)American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 330-353

[5] Crowley JJ(2006)Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials Lung Cancer 51 335-345

[6] LeBlanc M(2001)Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial Lancet 357 1478-1484

[7] Livingston RB(2005)A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer Jpn J Clin Oncol 35 181-187

[8] Pfister DG(2005)Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin Ann Oncol 16 602-610

[9] Johnson DH(2001)Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan Semin Oncol 28 15-20

[10] Azzoli CG(2001)Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial Ann Oncol 12 89-94

[1] Donnadieu N(1991)Chemotherapy of non-small cell bronchial cancers. Meta-analysis of the literature as a function of the extent of the disease Rev Mal Respir 8 197-204

[2] Paesmans M(1995)Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials Bmj 311 899-909

[3] Sculier JP(1991)Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest oncology group experience J Clin Oncol 9 1618-1626

[4] Albain KS(2004)American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 330-353

[5] Crowley JJ(2006)Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials Lung Cancer 51 335-345

[6] LeBlanc M(2001)Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial Lancet 357 1478-1484

[7] Livingston RB(2005)A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer Jpn J Clin Oncol 35 181-187

[8] Pfister DG(2005)Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin Ann Oncol 16 602-610

[9] Johnson DH(2001)Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan Semin Oncol 28 15-20

[10] Azzoli CG(2001)Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial Ann Oncol 12 89-94